CU technology providing hope for patients with liver disease

A promising new test developed at CU Anschutz and HepQuant LLC may enable a physician to detect liver disease, measure the severity of the disease, and predict risk for future complications. HepQuant is among the 141 startup companies sprung from CU technology discoveries over the past two decades.